Symbols

ALKS

Alkermes·NASDAQ

--(--)

ALKS fundamentals

ALKS Q4 2025 Earnings

Alkermes (ALKS) released its earnings on Feb 25, 2026: revenue was 384.55M (YoY -10.57%), beat estimates; EPS was 0.4677 (YoY -55.46%), beat estimates.

Revenue / YoY

384.55M

-10.57%

EPS / YoY

0.4677

-55.46%

Report date

Feb 25, 2026

ALKS Earnings Call Summary for Q4,2025

2026 Growth Ambition: $1.7B+ revenue, $370M+ EBITDA, driven by LUMRYZ ($350M+), alixorexton Phase III, and ADHD/fatigue pipeline.
Alixorexton Milestone: Phase III in narcolepsy to start Q2, targeting split dosing for extended wakefulness.
Avadel Synergy: LUMRYZ adds sleep medicine expertise, with 2026 net sales guidance of $350-$370M.
Pipeline Expansion: ALKS 7290 ADHD Phase Ib and ALKS 4510 fatigue Phase IIa to begin 2026, alongside valiloxybate development.
Leadership Transition: Richard Pops remains Chairman, Blair Jackson becomes CEO, positioning for long-term growth.

Earnings

EPS

Revenue

Revenue & Expenses

ALKS has released its 2025 Q4 earnings report, with revenue of 384.55M, reflecting a YoY change of -10.57%, and net profit of 49.34M, showing a YoY change of -66.32%. The Sankey diagram below clearly presents ALKS's revenue sources and cost distribution.

Key Indicators

Alkermes (ALKS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Alkermes (ALKS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Alkermes (ALKS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Alkermes (ALKS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown